SCHEMBL3014012

SCHEMBL3014012

COc1ccc(S(=O)(=O)N2CCN(c3nc(Cc4ccc(Cl)c(Cl)c4)cs3)CC2)cc1OC

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.49
HTT P42858 3/20 0.49
POLB P06746 1/20 0.49
GPBAR1 Q8TDU6 1/20 0.48
HDAC3 O15379 2/20 0.48
HDAC4 P56524 2/20 0.48
HDAC1 Q13547 2/20 0.48
HDAC7 Q8WUI4 2/20 0.48
HDAC2 Q92769 2/20 0.48
HDAC10 Q969S8 2/20 0.48
HDAC11 Q96DB2 2/20 0.48
HDAC8 Q9BY41 2/20 0.48
HDAC6 Q9UBN7 2/20 0.48
HDAC9 Q9UKV0 2/20 0.48
HDAC5 Q9UQL6 2/20 0.48
LMNA P02545 4/20 0.48
HSD17B10 Q99714 2/20 0.48
USP2 O75604 1/20 0.48
GLA P06280 1/20 0.48
MAPK1 P28482 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3016611 0.96 TSHR (0.47) TSHRHTTPOLBGPBAR1HDAC3
SCHEMBL3013884 0.93 TSHR (0.53) TSHRHTTPOLBGPBAR1HDAC3
SCHEMBL3015558 0.92 PKM (0.49) TSHRHTTPOLBGPBAR1HDAC3
SCHEMBL3008887 0.92 PKM (0.49) TSHRHTTPOLBGPBAR1HDAC3
SCHEMBL3019139 0.92 TSHR (0.50) TSHRHTTPOLBGPBAR1HDAC3
SCHEMBL3007865 0.90 GAA (0.49) TSHRHTTPOLBGPBAR1HDAC3
SCHEMBL3002337 0.90 TSHR (0.50) TSHRHTTPOLBGPBAR1HDAC3
SCHEMBL3021973 0.90 THRB (0.47) POLBLMNAHSD17B10USP2MAPK1
SCHEMBL3017911 0.89 HTT (0.54) TSHRHTTPOLBGPBAR1HDAC3
SCHEMBL3003877 0.89 TSHR (0.51) TSHRHTTPOLBGPBAR1HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA TSHR 3320/4885HTT 2/4885POLB 4649/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.